Stock CERENIS THERAPEUTICS
Add to a list
To use this feature you must be a member
Log inSign up

News Cerenis Therapeutics LIQUIDNET SYSTEMS

Equities

FR0012616852

End-of-day quote LIQUIDNET SYSTEMS
Other stock markets
 		5-day change 1st Jan Change
- EUR -.--% Intraday chart for Cerenis Therapeutics -.--% -.--%
06-14 Abionyx: positive response from FDA, share price rises CF
06-13 ABIONYX Pharma Completes Pre-IND Meeting with the FDA for CER-001 Phase 2b/3 Clinical Trial for Patients with Sepsis CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
ABIONYX decides on a capital increase with cancellation of preferential subscription rights for the benefit of a category of persons through the issue of shares with warrants for an amount of c.€3.4 million
BU
Abionyx: positive response from FDA, share price rises
CF
ABIONYX Pharma : has completed a successful pre IND meeting with the FDAfor CER 001 Phase 2b/3 Clinical Trial for Patients with Sepsis
PU
ABIONYX Pharma has completed a successful pre-IND meeting with the FDA for CER-001 Phase 2b/3 Clinical Trial for Patients with Sepsis
BU
ABIONYX Pharma has completed a successful pre-IND meeting with the FDA for CER-001 Phase 2b/3 Clinical Trial for Patients with Sepsis
BU
ABIONYX Pharma Completes Pre-IND Meeting with the FDA for CER-001 Phase 2b/3 Clinical Trial for Patients with Sepsis
CI
ABIONYX Pharma Provides an Update on Its Activity and Cash Position for the 1st Quarter 2024
BU
ABIONYX Pharma: Availability of the Universal Registration Document for the Year 2023
BU
Abionyx Pharma: to benefit from a 1ME grant from Bpifrance
CF
ABIONYX Pharma - Bpifrance Supports the Development of CER-001 in Ophthalmology With a Nearly €1 Million Non-dilutive Innovation Grant
BU
Abionyx: reduced net loss in 2023
CF
ABIONYX Pharma Announces Its 2023 Full-Year Financial Results
BU
ABIONYX Pharma SA Reports Earnings Results for the Full Year Ended December 31, 2023
CI
ABIONYX Pharma announces its financial calendar for the year 2024
BU
Abionyx: CSL Behring fails in heart disease trial
CF
ABIONYX Pharma SA Acknowledges the Clinical Results of the Phase 3 Aegis-Ii Study Evaluating the Efficacy and Safety of Csl Behring?S Human-Plasma-Derived Apoa-I, CSL112
CI
Abionyx: former AbbVie executive appointed CMO
CF
ABIONYX Pharma Appoints Rob Scott as Chief Medical Officer and Head of R&D
CI
Abionyx: Successful completion of third GMP batch of CER-001
CF
2,867,986 Ordinary Shares of ABIONYX Pharma SA are subject to a Lock-Up Agreement Ending on 7-DEC-2023.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ABNX Stock
  4. Stock
  5. News Cerenis Therapeutics